Selective lipoprotein(a)- and remnant-directed therapies
Selective lipoprotein(a)- and remnant-directed therapies has been studied in 1 paper since 2026: none in people yet, 1 review; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Oct 31, 2026: “Atherogenic lipoprotein particles and premature coronary artery disease: from molecular mechanisms to precision prevention”.
1 paper studies itUpdated
1 new paper in 30 daysSee all 1 papers on selective lipoprotein(a)- and remnant-directed therapies
Latest
1 paper in 12 monthsFrontiers in Cardiovascular Medicine
Atherogenic lipoprotein particles and premature coronary artery disease: from molecular mechanisms to precision prevention
ReviewMechanisms